Oxford University Press

SHERPA: Yellow

People

  1. Drilon
    Drilon
  2. Motzer
    Motzer
  3. Mellinghoff
    Mellinghoff
  4. Shuman
    Shuman
  5. Rosenblum
    Rosenblum
  6. Dunkel
    Dunkel
  7. Karajannis
    Karajannis
  8. Saltz
    Saltz
  9. Souweidane
    Souweidane
  10. Panageas
    Panageas

Groups

  1. Department of Medicine (1995)
  2. Solid Tumor Oncology Division (1624)
  3. GSK Faculty (765)
  4. Survivorship Research (639)
  5. Population Sciences Research Program (615)
  6. Epidemiology and Biostatistics (465)
  7. Department of Pathology and Laboratory Medicine (415)
  8. Gastrointestinal Oncology Service (386)
  9. Genitourinary Oncology Service (367)
  10. Tow Center for Developmental Oncology (TCDO) (352)
Search Within
Formats
  1. Journal Article (2131)
  2. Meeting Abstract (2072)
  3. Book Section (192)
  4. Review (92)
  5. Editorial (84)
  6. Guidelines (36)
  7. Correspondence (26)
  8. Book Whole (18)
  9. Conference Paper (15)
  10. Research Letter (10)
Groups
  1. Department of Medicine (1995)
  2. Solid Tumor Oncology Division (1624)
  3. GSK Faculty (765)
  4. Survivorship Research (639)
  5. Population Sciences Research Program (615)
  6. Epidemiology and Biostatistics (465)

More Groups

People
  1. Lisa De Angelis (119)
  2. Alexander Drilon (108)
  3. Robert Motzer (96)
  4. Ingo Mellinghoff (93)
  5. Stewart Shuman (88)
  6. Marc Rosenblum (87)

More People

Years
  1. 2025 (129)
  2. 2024 (304)
  3. 2023 (320)
  4. 2022 (331)
  5. 2021 (323)
  6. 2020 (325)

More Years

Publications
  1. Annals of Oncology (1670)
  2. Neuro-Oncology (855)
  3. JNCI: Journal of the National Cancer Institute (492)
  4. Nucleic Acids Research (210)
  5. Clinical Infectious Diseases (140)
  6. American Journal of Clinical Pathology (106)

More Publications

Results (4676)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Pharmacokinetic (PK) analysis of concurrent administration of enzalutamide (enza) and crizotinib (crizo) in patients with metastatic castration resistant prostate cancer (CRPC)
    Meeting Abstract

    Tripathi, A.; Supko, J. G.; Gray, K. P.; Melnick, Z.; Taplin, M. E.; Choudhury, A. D.; Pomerantz, M.; Bellmunt, J.; Yu, C.; Sun, Z.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Pembrolizumab for high-risk (HR) non-muscle invasive bladder cancer (NMIBC) unresponsive to bacillus Calmette-Guérin (BCG): Phase II KEYNOTE-057 trial
    Meeting Abstract

    de Wit, R.; Kulkarni, G. S.; Uchio, E.; Singer, E. A.; Krieger, L.; Grivas, P.; Bajorin, D.; Seo, H. K.; Mourey, L.; Kamat, A.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Treatment-free interval (TFI) following discontinuation of first-line nivolumab plus ipilimumab (N+I) or sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC): CheckMate 214 analysis
    Meeting Abstract

    McDermott, D. F.; Rini, B. I.; Motzer, R. J.; Tannir, N. M.; Escudier, B.; Kollmannsberger, C. K.; Hammers, H. J.; Porta, C.; George, S.; Donskov, F.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Assessment of disease burden in the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (HCC)
    Meeting Abstract

    Blanc, J. F.; Meyer, T.; Cheng, A. L.; El-Khoueiry, A. B.; Cicin, I.; Chen, Y.; Bolondi, L.; Dadduzio, V.; Baron, A.; Lin, Z. Z.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • A pilot study of gemcitabine, nab-paclitaxel, PEGPH20 (PAG) and rivaroxaban for advanced pancreatic adenocarcinoma: Interim safety and efficacy analysis
    Meeting Abstract

    Yu, K.; Mantha, S.; Tjan, C.; Kaufmann, E.; Brenner, R. B.; Lowery, M.; Ku, G.; Raj, N.; Shcherba, M.; Goldberg, Z.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Interim results of fight-202, a phase II, open-label, multicenter study of INCB054828 in patients (pts) with previously treated advanced/metastatic or surgically unresectable cholangiocarcinoma (CCA) with/without fibroblast growth factor (FGF)/FGF receptor (FGFR) genetic alterations
    Meeting Abstract

    Hollebecque, A.; Borad, M.; Sahai, V.; Catenacci, D. V. T.; Murphy, A.; Vaccaro, G.; Paulson, A.; Oh, D. Y.; Féliz, L.; Lihou, C.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Phase III KEYNOTE-585 study of chemotherapy (Chemo) + pembrolizumab (Pembro) vs chemo + placebo as neoadjuvant/adjuvant treatment for patients (pts) with gastric or gastroesophageal junction (G/GEJ) cancer
    Meeting Abstract

    Bang, Y. J.; Van Cutsem, E.; Fuchs, C. S.; Ohtsu, A.; Tabernero, J.; Ilson, D. H.; Hyung, W. J.; Strong, V. E.; Goetze, T. O.; Yoshikawa, T.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Preliminary results from TRITON2: A phase II study of rucaparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination repair (HRR) gene alterations
    Meeting Abstract

    Abida, W.; Bryce, A. H.; Vogelzang, N. J.; Amato, R. J.; Percent, I.; Shapiro, J. D.; McDermott, R.; Hussain, A.; Patnaik, A.; Petrylak, D.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Larotrectinib efficacy and safety in TRK fusion cancer: An expanded clinical dataset showing consistency in an age and tumor agnostic approach
    Meeting Abstract

    Lassen, U. N.; Albert, C. M.; Kummar, S.; van Tilburg, C. M.; Dubois, S. G.; Geoerger, B.; Mascarenhas, L.; Federman, N.; Schilder, R. J.; Doz, F.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Phase I clinical and translational evaluation of AZD6738 in combination with durvalumab in patients (pts) with lung or head and neck carcinoma
    Meeting Abstract

    Krebs, M.; Lopez, J.; El-Khoueiry, A.; Bang, Y. J.; Postel-Vinay, S.; Abidah, W.; Im, S. A.; Khoja, L. T.; Standifer, N.; Jones, G. N.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save